Outcomes Following Candiduria in Extremely Low Birth Weight Infants

Department of Pediatrics, Duke University, Durham, NC 27715, USA.
Clinical Infectious Diseases (Impact Factor: 8.89). 12/2011; 54(3):331-9. DOI: 10.1093/cid/cir800
Source: PubMed


Candidiasis carries a significant risk of death or neurodevelopmental impairment (NDI) in extremely low birth weight infants (ELBW; <1000 g). We sought to determine the impact of candiduria in ELBW preterm infants.
Our study was a secondary analysis of the Neonatal Research Network study Early Diagnosis of Nosocomial Candidiasis. Follow-up assessments included Bayley Scales of Infant Development examinations at 18-22 months of corrected age. Risk factors were compared between groups using exact tests and general linear modeling. Death, NDI, and death or NDI were compared using generalized linear mixed modeling.
Of 1515 infants enrolled, 34 (2.2%) had candiduria only. Candida was isolated from blood only (69 of 1515 [4.6%]), cerebrospinal fluid (CSF) only (2 of 1515 [0.1%]), other sterile site only (not urine, blood, or CSF; 4 of 1515 [0.3%]), or multiple sources (28 of 1515 [2%]). Eleven infants had the same Candida species isolated in blood and urine within 3 days; 3 (27%) had a positive urine culture result first. Most urine isolates were Candida albicans (21 of 34 [62%]) or Candida parapsilosis (7 of 34 [29%]). Rate of death or NDI was greater among those with candiduria (50%) than among those with suspected but not proven infection (32%; odds ratio, 2.5 [95% confidence interval, 1.2-5.3]) after adjustment. No difference in death and death or NDI was noted between infants with candiduria and those with candidemia.
These findings provide compelling evidence that ELBW infants with candiduria are at substantial risk of death or NDI. Candiduria in ELBW preterm infants should prompt a systemic evaluation (blood, CSF, and abdominal ultrasound) for disseminated Candida infection and warrants treatment.

Download full-text


Available from: Barbara J Stoll,
27 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Candidemia is a cause of significant morbidity and mortality in neonates and children. Risk factors for candidemia include prolonged stay in the intensive care unit, prior antibiotic therapy, immunosuppression related to malignancy, transplantation, use of immunosuppressants or steroids, neutropenia, need for mechanical ventilation, use of vasopressors, recent surgery (especially gastrointestinal), intravenous catheters and receipt of total parenteral nutrition. Candida albicans followed by C. parapsilosis are the most common species causing candidemia in children. Clinicians must be aware of the risk factors for candidemia and the local epidemiology of Candida species in order to direct antifungal therapy appropriately. Ongoing efforts to minimize health care-associated candidemia through infection control practices, judicious antimicrobial use and antifungal prophylaxis in appropriate situations are important to reducing Candida-associated morbidity and mortality in neonates and children.
    Current Fungal Infection Reports 12/2012; 6(4). DOI:10.1007/s12281-012-0113-y
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hospitalized children of all ages are at risk of invasive fungal disease and deserve studies that can describe optimal dosing for their unique physiology. Linear weight-based extrapolation from adult data is inadequate and too often results in drug underexposure or overexposure. This places children at risk for unacceptable therapeutic failure or toxicity. New legislation in the last 15 years has made it advantageous, and in some cases mandatory, for drug companies to include pediatric trials in new drug development. We recommend that the study of antifungal therapeutics routinely include PK and dosing in children of all ages, especially those <2 years of age where variability and maturational changes are highest. In drugs with high variability and a narrow therapeutic window, therapeutic drug monitoring should be considered. Finally, when recommending a dose, the therapeutic target must reflect the natural history of the disease in the target population. Incorporating these recommendations in the development of new antifungals will lead to safer and more effective antifungal therapy in children.
    The Pediatric Infectious Disease Journal 03/2012; 31(6):635-7. DOI:10.1097/INF.0b013e31824f8426 · 2.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Candida infections are a major cause of morbidity and mortality in neonatal intensive care units. Mortality following Candida bloodstream infections is as high as 40%, and neurodevelopmental impairment is common among survivors. Because invasive fungal infections are common and extremely difficult to diagnose, empirical treatment with antifungal therapy should be considered in high-risk, low-birth-weight infants who fail to quickly respond to empirical antibacterial treatment. Risk factors to consider when deciding to administer empirical antifungal therapy include: prior exposure to third-generation cephalosporins, extreme prematurity, and presence of central venous catheters.
    Early human development 05/2012; 88 Suppl 2(Suppl 2):S6-S10. DOI:10.1016/S0378-3782(12)70004-X · 1.79 Impact Factor
Show more